Pages that link to "Q24293582"
Jump to navigation
Jump to search
The following pages link to Mechanism of CDK5/p25 binding by CDK inhibitors (Q24293582):
Displaying 50 items.
- Cyclin dependent kinase 5 regulatory subunit 1 (Q21109701) (← links)
- cyclin dependent kinase 5 (Q21116933) (← links)
- The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose (Q24314582) (← links)
- Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis (Q24623805) (← links)
- Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1 (Q24675401) (← links)
- Roscovitine in cancer and other diseases (Q26799874) (← links)
- Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design (Q28533443) (← links)
- RSK2 Binding Models Delineate Key Features for Activity (Q30432330) (← links)
- A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor (Q30437056) (← links)
- Roscovitine Inhibits EBNA1 Serine 393 Phosphorylation, Nuclear Localization, Transcription, and Episome Maintenance (Q33786506) (← links)
- Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp. (Q34244752) (← links)
- Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening (Q34625383) (← links)
- Niemann-Pick type C pathogenesis and treatment: from statins to sugars. (Q34632493) (← links)
- Selectivity and potency of cyclin-dependent kinase inhibitors (Q34651981) (← links)
- Structure–activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors (Q34706737) (← links)
- Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders (Q34914245) (← links)
- Protein Kinase−Inhibitor Database: Structural Variability of and Inhibitor Interactions with the Protein Kinase P-Loop (Q35606325) (← links)
- Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis (Q36709312) (← links)
- Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. (Q36836607) (← links)
- Protein kinases in organ ischemia and reperfusion (Q37211896) (← links)
- Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period (Q37280604) (← links)
- Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators (Q37289231) (← links)
- Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages (Q37338910) (← links)
- Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore (Q37503295) (← links)
- The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35. (Q37518226) (← links)
- Tau as a Therapeutic Target for Alzheimers Disease (Q37890451) (← links)
- Cyclin-dependent kinases: bridging their structure and function through computations. (Q37924806) (← links)
- Kinetics, in silico docking, molecular dynamics, and MM‐GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP‐binding site inhibitors: The role of water molecules examined (Q38337597) (← links)
- Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy (Q38542939) (← links)
- Insights into Ligand-Protein Binding from Local Mechanical Response. (Q38684570) (← links)
- Structural basis of valmerins as dual inhibitors of GSK3β/CDK5. (Q39142231) (← links)
- Binding Mechanism of Inhibitors to CDK5/p25 Complex: Free Energy Calculation and Ranking Aggregation Analysis (Q39460467) (← links)
- Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease (Q39630367) (← links)
- 7-Bromoindirubin-3'-oxime induces caspase-independent cell death (Q40279500) (← links)
- Automating crystallographic structure solution and refinement of protein-ligand complexes. (Q41940007) (← links)
- Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5. (Q41968676) (← links)
- Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP. (Q42549261) (← links)
- S-nitrosylation of cyclin-dependent kinase 5 (cdk5) regulates its kinase activity and dendrite growth during neuronal development. (Q42845661) (← links)
- Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design (Q43986703) (← links)
- Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors (Q44045827) (← links)
- Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics (Q46890342) (← links)
- Structure-based discovery of cyclin-dependent protein kinase inhibitors. (Q47423882) (← links)
- Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA. (Q47733092) (← links)
- Epigenetic modulation of Cdk5 contributes to memory deficiency induced by amyloid fibrils (Q48532158) (← links)
- Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations. (Q51181955) (← links)
- Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations. (Q51766677) (← links)
- Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5. (Q54441914) (← links)
- Studying the mechanism that enables paullones to selectively inhibit glycogen synthase kinase 3 rather than cyclin-dependent kinase 5 by molecular dynamics simulations and free-energy calculations. (Q54667185) (← links)
- Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease. (Q55073370) (← links)
- Tau-targeting therapies for Alzheimer disease (Q57178723) (← links)